Last reviewed · How we verify
usual dose of valsartan
At a glance
| Generic name | usual dose of valsartan |
|---|---|
| Sponsor | Dong-A University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Polypill and Colchicine for Risk Reduction in Atherosclerotic Cardiovascular Disease (PHASE3)
- Heart Failure Polypill at a Safety Net Hospital (PHASE2)
- Sacubitril/Valsartan in Resistant Hypertension (PHASE2)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- Timely Recovery After Subclinical Heart Failure (PHASE4)
- Sacubitril-valsartan Versus Usual Anti-hypertensives in LVAD (PHASE4)
- Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection? (PHASE3)
- Sacubitril/Valsartan vs Lifestyle in Hypertrophic Cardiomyopathy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- usual dose of valsartan CI brief — competitive landscape report
- usual dose of valsartan updates RSS · CI watch RSS
- Dong-A University portfolio CI